- Home
- ELVN vs ROOT Comparison
ELVN vs ROOT Comparison
Compare ELVN & ROOT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ELVN
- ROOT
- Stock Information
- Founded
- ELVN 2016
- ROOT 2015
- Country
- ELVN United States
- ROOT United States
- Employees
- ELVN N/A
- ROOT N/A
- Industry
- ELVN Biotechnology: Pharmaceutical Preparations
- ROOT Property-Casualty Insurers
- Sector
- ELVN Health Care
- ROOT Finance
- Exchange
- ELVN Nasdaq
- ROOT Nasdaq
- Market Cap
- ELVN 1.1B
- ROOT 1.3B
- IPO Year
- ELVN 2020
- ROOT 2020
- Fundamental
- Price
- ELVN $21.47
- ROOT $85.31
- Analyst Decision
- ELVN Strong Buy
- ROOT Buy
- Analyst Count
- ELVN 5
- ROOT 9
- Target Price
- ELVN $37.80
- ROOT $58.38
- AVG Volume (30 Days)
- ELVN 246.0K
- ROOT 323.1K
- Earning Date
- ELVN 03-13-2025
- ROOT 02-19-2025
- Dividend Yield
- ELVN N/A
- ROOT N/A
- EPS Growth
- ELVN N/A
- ROOT N/A
- EPS
- ELVN N/A
- ROOT N/A
- Revenue
- ELVN N/A
- ROOT $1,044,599,999.00
- Revenue This Year
- ELVN N/A
- ROOT N/A
- Revenue Next Year
- ELVN N/A
- ROOT $8.55
- P/E Ratio
- ELVN N/A
- ROOT N/A
- Revenue Growth
- ELVN N/A
- ROOT 215.11
- 52 Week Low
- ELVN $10.90
- ROOT $7.22
- 52 Week High
- ELVN $30.03
- ROOT $118.15
- Technical
- Relative Strength Index (RSI)
- ELVN 42.14
- ROOT 59.04
- Support Level
- ELVN $20.16
- ROOT $71.75
- Resistance Level
- ELVN $23.08
- ROOT $89.92
- Average True Range (ATR)
- ELVN 1.60
- ROOT 5.39
- MACD
- ELVN -0.09
- ROOT 1.55
- Stochastic Oscillator
- ELVN 25.14
- ROOT 76.56
About ELVN Enliven Therapeutics Inc.
Enliven Therapeutics Inc is a clinical-stage precision oncology company focused on the discovery and development of potentially first-in-class precision oncology therapies. Enliven's programs are designed to address issues such as tolerability, combinability, resistance and disease escape through brain metastases. Its product candidates include ELVN-001 which is a potent, selective, small molecule kinase inhibitor designed to specifically target the BCR-ABL gene fusion, the oncogenic driver for patients with chronic myeloid leukemia, and the ELVN-002 which is central nervous system (CNS) penetrant and irreversible HER2 inhibitor with activity against wild type HER2 and various HER2 mutations.
About ROOT Root Inc.
Root Inc develops and launches a direct-to-consumer personal automobile insurance and mobile technology company. The company is a direct-to-consumer personal auto insurance, renters insurance and mobile technology company. It generates revenue from the sale of auto insurance policies within the United States.